Primary Care Respiratory Journal Primary Care Respiratory Group UK International Primary Care Respiratory Group Primary Care Respiratory Group UK International Primary Care Respiratory Group
Home
About the PCRJ
Articles in Press
Current Issue
All Issues
Translations
Alerts
Most popular articles
Editorial Board
Advertising
Search Tools
Disclaimer and Legal Notices
Citation Exporter

Export the citation data for this article directly into your bibliographic software by selecting one of the formats listed here:
*If required, consult your bibliographic software documentation on importing RIS format files.

If you do not have bibliographic software, you may copy and paste the bibliographic data below:

Reference in Vancouver style
Johansson G, Lindberg A, Romberg K, Nordstrom L, Gerken F, Roquet A. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim Care Resp J 2008;17(3):169-175. DOI: http://dx.doi.org/10.3132/pcrj.2008.00037

Citation details
Johansson G, Lindberg A, Romberg K, Nordstrom L, Gerken F, Roquet A

Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD

(2008) Prim Care Resp J 17 (3), pp. 169-175.

DOI: http://dx.doi.org/10.3132/pcrj.2008.00037

Article web page: http://www.thepcrj.org/journ/view_article.php?article_id=569

PDF url: http://www.thepcrj.org/journ/vol17/17_3_169_175.pdf

Abstract:
AIMS: Evaluation of tiotropium efficacy in patients with mild chronic obstructive pulmonary disease (COPD) defined by the 2003 Swedish Society of Respiratory Medicine guidelines (post-bronchodilator FEV1/FVC <70%; FEV1 >60% predicted). METHODS: In this 12-week, randomised, double-blind, placebo-controlled study of tiotropium 18 mcg once daily versus placebo, respiratory function was assessed on Days 1, 15 and 85 (baseline: pre-dose Day 1). RESULTS: Mean+/-SD baseline FEV1 (% predicted) was 73.4+/-12.5 (tiotropium, n=107; placebo, n=117). Tiotropium significantly improved change from baseline in area under the curve from pre-dose to 2 hours post-dose (AUC0-2 h) FEV1 versus placebo, by 166+/-26 mL (mean+/-SE) at study end (p<0.0001). With tiotropium, there were significant increases in the change in AUC0-2 h FVC versus baseline, and trough FEV1 and FVC, versus placebo, on all test days (p<0.01). Adverse event rates were similar. CONCLUSION: Compared with placebo, tiotropium improved lung function in patients with mild COPD.

Keywords:
Chronic obstructive pulmonary disease, mild, moderate, tiotropium






If you have any comments, queries or difficulties exporting citations, please contact info@danzigdesigns.com

© Danzig Designs


Website developed and maintained by danzigdesigns.com